...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The EPMA journal. >Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct diabetes-associated deficits
【24h】

Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct diabetes-associated deficits

机译：糖尿病性视网膜病发病机理中的内皮祖功能异常：纠正糖尿病相关缺陷的治疗方案

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Progressive obliteration of the retinal microvessels is a characteristic of diabetic retinopathy and the resultant retinal ischemia can lead to sight-threatening macular edema, macular ischemia and ultimately preretinal neovascularization. Bone marrow derived endothelial progenitor cells (EPCs) play a critical role in vascular maintenance and repair. There is still great debate about the most appropriate markers that define an EPC. EPCs can be isolated using cell sorting by surface phenotype selection or in vitro cell culture. For freshly isolated cells, EPC cell sorting is heavily dependent on the surface markers used; EPCs can also be isolated by in vitro propagation of heterogeneous mixtures of cells in culture using adhesion to specific substrates and cell growth characteristics. in vitro isolation enables consistent reproducibility and using this approach at least two distinct types of EPCs with different angiogenic properties have been identified from adult peripheral and umbilical cord blood; early EPCs (eEPCs) and late outgrowth endothelial progenitor cells (OECs). Emerging studies demonstrate the potential of these cells in revascularization of ischemic/injured retina in animal models of retinal disease. Since ischemic retinopathies are leading causes of blindness, they are a potential disease target for EPC-based therapy. In this chapter, we summarize the current knowledge about EPCs and discuss the possibility of cellular therapy for treatment of diabetic macular ischemia and the vasodegenerative phase of diabetic retinopathy. We also report current pharmacological options that can be utilized to correct diabetes associated defects in EPCs so as to enhance the therapeutic utility of these cells.
机译：摘要视网膜微血管的逐渐闭塞是糖尿病性视网膜病变的一个特征，所产生的视网膜缺血可导致威胁视力的黄斑水肿，黄斑缺血并最终导致视网膜前新生血管形成。骨髓来源的内皮祖细胞（EPC）在血管维持和修复中起着至关重要的作用。关于定义EPC的最合适的标记，仍然存在很多争论。可以通过表面表型选择或体外细胞培养使用细胞分选方法分离EPC。对于新鲜分离的细胞，EPC细胞分选在很大程度上取决于所使用的表面标记。也可以通过使用对特定底物的粘附力和细胞生长特性，通过培养中细胞异质混合物的体外繁殖来分离EPC。体外分离能够实现一致的可重复性，并且使用这种方法，从成人外周血和脐带血中至少鉴定出两种具有不同血管生成特性的EPC;早期的EPC（eEPC）和晚期的内皮祖细胞（OEC）。新兴的研究表明，在视网膜疾病动物模型中，这些细胞在缺血/受伤视网膜的血运重建中具有潜力。由于缺血性视网膜病是失明的主要原因，因此它们是基于EPC的治疗的潜在疾病靶标。在本章中，我们总结了有关EPC的最新知识，并讨论了细胞疗法治疗糖尿病性黄斑缺血和糖尿病性视网膜病变的血管生成阶段的可能性。我们还报告了目前可用于纠正EPC中与糖尿病相关的缺陷，从而增强这些细胞的治疗效用的药理学选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号